Non-analgesic effects of opioids: Neuroprotection in the retina

Current Pharmaceutical Design

Volumn 18, Issue 37, 2012, Pages 6101-6108

  Husain, Shahid ^a   Abdul, Yasir ^a   Potter, David E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Ischemia; Opioid; Opioid receptor; Retina; TNF

Indexed keywords

DELTA OPIATE RECEPTOR; GLUTAMIC ACID; MORPHINE; OPIATE; PROTEIN KINASE B; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CELL STRESS; CELL VIABILITY; HOMEOSTASIS; HUMAN; MOLECULAR MECHANICS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RETINA ISCHEMIA; REVIEW;

ANALGESICS, OPIOID; ANIMALS; HUMANS; INFLAMMATION MEDIATORS; ISCHEMIA; LIGANDS; NEUROPROTECTIVE AGENTS; OPIOID PEPTIDES; RECEPTORS, OPIOID; RETINAL DEGENERATION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873969519     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803582441     Document Type: Review

References (141)

1. Chen Y, Mestek A, Liu J, Hurley JA, Yu L. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 1993; 44: 8-12.
2. Minami, M., and Satoh, M. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res 1995; 23: 121-45.
3. Howells RD, Kilpatrick DL, Bailey LC, Noe M, Udenfriend S. Proenkephalin mRNA in rat heart. Proc Natl Acad Sci USA 1986; 83: 1960-3.
4. Wamsley JK, Palacios JM, Kuhar MJ. Autoradiographic localization of opioid receptors in the mammalian retina. Neurosci Lett 1981; 27: 19-24.
5. Husain S, Potter DE, Crosson CE. Opioid-receptor-activation protects the retina from ischemic injury. Invest Ophthalmol Vis Sci 2009; 50: 3853-9.
6. Husain S, Liou GI, Crosson CE. Opioid-receptor-activation: Suppression of ischemia/reperfusion-induced production of TNF-alpha in the retina. Invest Ophthalmol Vis Sci 2011; 52: 2577-83.
7. Schultz JE, Rose E, Yao Z, Gross, GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995; 268: H2157-61.
8. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther 2001; 89, 123-37.
9. Ferri S, Speroni E, Candeletti S, et al. Protection by opioids against gastric lesions caused by necrotizing agents. Pharmacology 1988; 36: 140-4.
10. Mayfield KP, D'Alecy LG. Delta-1 opioid agonist acutely increases hypoxic tolerance. J Pharmacol Exp Ther 1994; 268: 683-8.
11. Paradis P, Dumont M, Belichard P, Rouleau JL, Lemaire S, Brakier-Gingras L. Increased preproenkephalin A gene expression in the rat heart after induction of a myocardial infarction. Biochem Cell Biol 1992; 70: 593-8.
12. Chen TY, Goyagi T, Toung TJ, et al. Prolonged opportunity for ischemic neuroprotection with selective kappa-opioid receptor agonist in rats. Stroke 2004; 35: 1180-5.
13. Zhang J, Gibney GT, Zhao P, Xia Y. Neuroprotective role of deltaopioid receptors in cortical neurons. Am J Physiol Cell Physiol 2002; 282: C1225-34.
14. Meriney SD, Gray DB, Pilar G. Morphine-induced delay of normal cell death in the avian ciliary ganglion. Science 1985; 228: 1451-3.
15. Schmahl W, Funk R, Miaskowski U, Plendl J. Long-lasting effects of naltrexone, an opioid receptor antagonist, on cell proliferation in developing rat forebrain. Brain Res 1989; 486: 297-300.
16. Meriney SD, Ford MJ, Oliva D, Pilar G. Endogenous opioids modulate neuronal survival in the developing avian ciliary ganglion. J Neurosci 1991; 11: 3705-17.
17. Liang BT, Gross GJ. Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels. Circ Res 1999; 84: 1396-1400.
18. Zhao P, Huang Y, Zuo Z. Opioid preconditioning induces opioid receptor-dependent delayed neuroprotection against ischemia in rats. J Neuropathol Exp Neurol 2006; 65: 945-52.
19. Rogers TJ, Peterson PK. Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 2003; 24: 116-21.
20. Bodnar RJ, Klein GE. Endogenous opiates and behavior: 2003. Peptides 2004; 25: 2205-56.
21. Malinowski K, Shock EJ, Rochelle P, Kearns CF, Guirnalda PD, McKeever KH. Plasma beta-endorphin, cortisol and immune responses to acute exercise are altered by age and exercise training in horses. Equine Vet J Suppl 2006; 36: 267-73.
22. Stanojevic S, Mitic K, Vujic V, Kovacevic-Jovanovic V, Dimitrijevic M. Beta-endorphin differentially affects inflammation in two inbred rat strains. Eur J Pharmacol 2006; 549: 157-65.
23. Cui Y, Lee TF, Wang LC. State-dependent changes of brain endogenous opioids in mammalian hibernation. Brain Res Bull 1996; 40: 129-33.
24. Drew KL, Rice ME, Kuhn TB, Smith MA. Neuroprotective adaptations in hibernation: therapeutic implications for ischemiareperfusion, traumatic brain injury and neurodegenerative diseases. Free Radic Biol Med 2001; 31: 563-73.
25. Drew KL, Buck CL, Barnes BM, Christian SL, Rasley BT, Harris MB. Central nervous system regulation of mammalian hibernation: implications for metabolic suppression and ischemia tolerance. J Neurochem 2007; 102: 1713-26.
26. Oeltgen PR, Nilekani SP, Nuchols PA, Spurrier WA, Su TP. Further studies on opioids and hibernation: delta opioid receptor ligand selectively induced hibernation in summer-active ground squirrels. Life Sci 1988; 43: 1565-74.
27. Govindaswami M, Brown SA, Yu J, et al. Delta 2-specific opioid receptor agonist and hibernating woodchuck plasma fraction provide ischemic neuroprotection. Acad Emerg Med 2008; 15: 250-7.
28. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci 1984; 7: 223-55.
29. Maslov LN, Lishmanov YB. Change in opioid peptide level in the heart and blood plasma during acute myocardial ischaemia complicated by ventricular fibrillation. Clin Exp Pharmacol Physiol 1995; 22: 812-6.
30. Chien GL, Van Winkle DM. Naloxone blockade of myocardial ischemic preconditioning is stereoselective. J Mol Cell Cardiol 1996; 28: 1895-1900.
31. Peart JN, Gross ER, Gross GJ. Opioid-induced preconditioning: recent advances and future perspectives. Vascul Pharmacol 2005; 42: 211-8.
32. Rubaj A, Gustaw K, Zgodzinski W, Kleinrok Z, Sieklucka-Dziuba M. The role of opioid receptors in hypoxic preconditioning against seizures in brain. Pharmacol Biochem Behav 2000; 67: 65-70.
33. Gannon RL, Terrian DM. U-50,488H inhibits dynorphin and glutamate release from guinea pig hippocampal mossy fiber terminals. Brain Res 1991; 548: 242-7.
34. Gross RA, Macdonald RL. Dynorphin A selectively reduces a large transient (N-type) calcium current of mouse dorsal root ganglion neurons in cell culture. Proc Natl Acad Sci USA 1987; 84: 5469-73.
35. Chao D, Bazzy-Asaad A, Balboni G, Salvadori S, Xia Y. Activation of DOR attenuates anoxic K+ derangement via inhibition of Na+ entry in mouse cortex. Cereb Cortex 2008; 18: 2217-27.
36. Chao D, Donnelly DF, Feng Y, Bazzy-Asaad A, Xia Y. Cortical delta-opioid receptors potentiate K+ homeostasis during anoxia and oxygen-glucose deprivation. J Cereb Blood Flow Metab 2007; 27: 356-68.
37. Hong SS, Qian H, Zhao P, Bazzy-Asaad A, Xia Y. Anisomycin protects cortical neurons from prolonged hypoxia with differential regulation of p38 and ERK. Brain Res 2007; 1149: 76-86.
38. Ma MC, Qian H, Ghassemi F, Zhao P, Xia Y. Oxygen-sensitive {delta}-opioid receptor-regulated survival and death signals: novel insights into neuronal preconditioning and protection. J Biol Chem 2005; 280: 16208-18.
39. Tian XS, Zhou F, Yang R, Xia Y, Wu GC, Guo JC. Effects of intracerebroventricular injection of delta-opioid receptor agonist TAN-67 or antagonist naltrindole on acute cerebral ischemia in rat. Sheng Li Xue Bao 2008; 60: 475-84.
40. Zhang J, Haddad GG, Xia Y. delta-, but not mu-and kappa-, opioid receptor activation protects neocortical neurons from glutamateinduced excitotoxic injury. Brain Res 2000; 885: 143-53.
41. Zhang J, Qian H, Zhao P, Hong SS, Xia Y. Rapid hypoxia preconditioning protects cortical neurons from glutamate toxicity through delta-opioid receptor. Stroke 2006; 37: 1094-9.
42. Chao D, Bazzy-Asaad A, Balboni G, Xia Y. delta-, but not mu-, opioid receptor stabilizes K(+) homeostasis by reducing Ca(2+) influx in the cortex during acute hypoxia. J Cell Physiol 2007; 212: 60-7.
43. Drago F, Panissidi G, Bellomio F, Dal Bello A, Aguglia E, Gorgone G. Effects of opiates and opioids on intraocular pressure of rabbits and humans. Clin Exp Pharmacol Physiol 1985; 12: 107-13.
44. Drago F, Gorgone G, Spina F, et al. Opiate receptors in the rabbit iris. Naunyn Schmiedebergs Arch Pharmacol 1980; 315: 1-4.
45. Selbach JM, Buschnack SH, Steuhl KP, Kremmer S, Muth-Selbach U. Substance P and opioid peptidergic innervation of the anterior eye segment of the rat: an immunohistochemical study. J Anat 2005; 206: 237-42.
46. Stone RA, Kuwayama Y, Laties AM. Regulatory peptides in the eye. Experientia 1987; 43: 791-800.
47. Drago F, Aguglia E, Dal Bello A, et al. Ocular instillation of naloxone increases intraocular pressure in morphine-addicted patients: a possible test for detecting misuse of morphine. Experientia 1985; 41: 266-7.
48. Murray RB, Adler MW, Korczyn AD. The pupillary effects of opioids. Life Sci 1983; 33: 495-509.
49. Fanciullacci M, Boccuni M, Pietrini U, Sicuteri F. The naloxone conjunctival test in morphine addiction. Eur J Pharmacol 1980; 61: 319-20.
50. Russell KR, Wang DR, Potter DE. Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist. Exp Eye Res 2000; 70: 675-82.
51. Wang D, Potter DE. Ocular action of an opioid peptide, DPDPE. J Ocul Pharmacol Ther 1996; 12: 131-9.
52. Russell KR, Potter DE. Dynorphin modulates ocular hydrodynamics and releases atrial natriuretic peptide via activation of kappaopioid receptors. Exp Eye Res 2002; 75: 259-70.
53. Moore TT, Potter DE. Kappa opioid agonist-induced changes in IOP: correlation with 3H-NE release and cAMP accumulation. Exp Eye Res 2001; 73: 167-78.
54. Potter DE, Russell KR, Manhiani M. Bremazocine increases Ctype natriuretic peptide levels in aqueous humor and enhances outflow facility. J Pharmacol Exp Ther 2004; 309: 548-53.
55. Chu TC, Potter DE. Ocular hypotension induced by electroacupuncture. J Ocul Pharmacol Ther 2002; 18: 293-305.
56. Kurusu M, Watanabe K, Nakazawa T, et al. Acupuncture for patients with glaucoma. Explore (NY) 2005; 1: 372-6.
57. Chien GL, Mohtadi K, Wolff RA, Van Winkle DM. Naloxone blockade of myocardial ischemic preconditioning does not require central nervous system participation. Basic Res Cardiol 1999; 94: 136-43.
58. Riazi-Esfahani M, Kiumehr S, Asadi-Amoli F, Lashay AR, Dehpour AR. Morphine pretreatment provides histologic protection against ischemia-reperfusion injury in rabbit retina. Retina 2008; 28: 511-7.
59. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab 2007; 27: 435-51.
60. Bang OY, Saver JL, Buck BH, et al. Impact of collateral flow on tissue fate in acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2008; 79: 625-9.
61. Johnston MV. Excitotoxicity in perinatal brain injury. Brain Pathol 2005; 15: 234-40.
62. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 2004; 23: 91-147.
63. Roth S, Dreixler JC, Shaikh AR, Lee KH, Bindokas V. Mitochondrial potassium ATP channels and retinal ischemic preconditioning. Invest Ophthalmol Vis Sci 2006; 47: 2114-24.
64. Roth S, Li B, Rosenbaum PS, Gupta H, Goldstein IM, Maxwell KM, Gidday JM. Preconditioning provides complete protection against retinal ischemic injury in rats. Invest Ophthalmol Vis Sci 1998; 39: 777-85.
65. Zhang X, Cheng M, Chintala SK. Kainic acid-mediated upregulation of matrix metalloproteinase-9 promotes retinal degeneration. Invest Ophthalmol Vis Sci 2004; 45: 2374-83.
66. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol 1999; 43 (Suppl 1): S102-28.
67. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estevez E. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 2004; 20: 155-7.
68. de Kozak Y, Cotinet A, Goureau O, Hicks D, Thillaye-Goldenberg B. Tumor necrosis factor and nitric oxide production by resident retinal glial cells from rats presenting hereditary retinal degeneration. Ocul Immunol Inflamm 1997; 5: 85-94.
69. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 2001; 42: 1787-94.
70. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 2006; 20: 1366-9.
71. Liu T, Clark RK, McDonnell PC, et al. Tumor necrosis factoralpha expression in ischemic neurons. Stroke 1994; 25: 1481-8.
72. Hsu H, Xiong J, Goeddel DV. (1995) The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81: 495-504.
73. Shen Y, Li R, Shiosaki K. Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line. J Biol Chem 1997; 272: 3550-3.
74. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med 2004; 8: 445-54.
75. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65.
76. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002; 22: RC216.
77. Kramer M, Dadon S, Hasanreisoglu M, et al. Proinflammatory cytokines in a mouse model of central retinal artery occlusion. Mol Vis 2009; 15: 885-94.
78. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res 2008; 173: 409-21.
79. Ertel W, Keel M, Bonaccio M, et al. Release of anti-inflammatory mediators after mechanical trauma correlates with severity of injury and clinical outcome. J Trauma 1995; 39: 879-85; discussion 885-7.
80. Shohami E, Bass R, Wallach D, Yamin A, Gallily R. Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. J Cereb Blood Flow Metab 1996; 16: 378-84.
81. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol 2000; 118: 666-73.
82. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia 2000; 32: 42-50.
83. Bonnet MP, Beloeil H, Benhamou D, Mazoit JX, Asehnoune K. The mu opioid receptor mediates morphine-induced tumor necrosis factor and interleukin-6 inhibition in toll-like receptor 2-stimulated monocytes. Anesth Analg 2008; 106: 1142-9, table of contents.
84. Garcia I, Perez-Castillo A, Moreno J, Alemany S. Beta-endorphin inhibits interleukin-2 release and expression of interleukin-2 receptors in concanavalin A-stimulated splenic lymphocytes. Lymphokine Cytokine Res 1992; 11: 339-45.
85. Takeba Y, Suzuki N, Kaneko A, Asai T, Sakane T. Endorphin and enkephalin ameliorate excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 2176-83.
86. Sheng WS, Hu S, Lokensgard JR, Peterson PK. U50,488 inhibits HIV-1 Tat-induced monocyte chemoattractant protein-1 (CCL2) production by human astrocytes. Biochem Pharmacol 2003; 65: 9-14.
87. Sharma SK, Klee WA, Nirenberg M. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 1975; 72: 3092-6.
88. Standifer KM, Pasternak GW. G proteins and opioid receptormediated signalling. Cell Signal 1997; 9: 237-48.
89. Kim MS, Cheong YP, So HS, et al. Protective effects of morphine in peroxynitrite-induced apoptosis of primary rat neonatal astrocytes: potential involvement of G protein and phosphatidylinositol 3-kinase (PI3 kinase). Biochem Pharmacol 2001; 61: 779-86.
90. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001; 81: 299-343.
91. Kazmi SM, Mishra RK. Comparative pharmacological properties and functional coupling of mu and delta opioid receptor sites in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1987; 32: 109-18.
92. Frey EA, Kebabian JW. A mu-opiate receptor in 7315c tumor tissue mediates inhibition of immunoreactive prolactin release and adenylate cyclase activity. Endocrinology 1984; 115: 1797-804.
93. North RA, Williams JT, Surprenant A, Christie MJ. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci USA 1987; 84: 5487-91.
94. Twitchell WA, Rane SG. Nucleotide-independent modulation of Ca(2+)-dependent K+ channel current by a mu-type opioid receptor. Mol Pharmacol 1994; 46: 793-8.
95. Wimpey TL, Chavkin C. Opioids activate both an inward rectifier and a novel voltage-gated potassium conductance in the hippocampal formation. Neuron 1991; 6: 281-9.
96. Grudt TJ, Williams JT. kappa-Opioid receptors also increase potassium conductance. Proc Natl Acad Sci USA 1993; 90: 11429-32.
97. Surprenant A, Shen KZ, North RA, Tatsumi H. Inhibition of calcium currents by noradrenaline, somatostatin and opioids in guinea-pig submucosal neurones. J Physiol 1990; 431: 585-608.
98. Wilding TJ, Womack MD, McCleskey EW. Fast, local signal transduction between the mu opioid receptor and Ca2+ channels. J Neurosci 1995; 15: 4124-32.
99. Hescheler J, Rosenthal W, Trautwein W, Schultz G. The GTPbinding protein, Go, regulates neuronal calcium channels. Nature 1987; 325: 445-7.
100. Iglesias M, Segura MF, Comella JX, Olmos G. Mu-opioid receptor activation prevents apoptosis following serum withdrawal in differentiated SH-SY5Y cells and cortical neurons via phosphatidylinositol 3-kinase. Neuropharmacology 2003; 44: 482-92.
101. Hou YN, Vlaskovska M, Cebers G, Kasakov L, Liljequist S, Terenius L. A mu-receptor opioid agonist induces AP-1 and NF-kappa B transcription factor activity in primary cultures of rat cortical neurons. Neurosci Lett 1996; 212: 159-62.
102. Dortch-Carnes J, Potter DE. Delta-opioid agonist-stimulated inositol phosphate formation in isolated, rabbit iris-ciliary bodies: role of G(i/o) proteins and Gbetagamma-subunits. Exp Eye Res 2003; 77: 647-52.
103. Chen L, Huang LY. Sustained potentiation of NMDA receptormediated glutamate responses through activation of protein kinase C by a mu opioid. Neuron 1991; 7: 319-26.
104. Welters ID, Fimiani C, Bilfinger TV, Stefano GB. NF-kappaB, nitric oxide and opiate signaling. Med Hypotheses 2000; 54: 263-8.
105. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 2006; 291: H827-34.
106. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000; 40: 389-430.
107. Centurion SA, Centurion LM, Souza ME, et al. Effects of ischemic liver preconditioning on hepatic ischemia/reperfusion injury in the rat. Transplant Proc 2007; 39: 361-4.
108. Gidday JM, Fitzgibbons JC, Shah AR, Park TS. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. Neurosci Lett 1994; 168: 221-4.
109. Kato H, Araki T, Murase K, Kogure K. Induction of tolerance to ischemia: alterations in second-messenger systems in the gerbil hippocampus. Brain Res Bull 1992; 29: 559-65.
110. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
111. Whitlock NA, Agarwal N, Ma JX, Crosson CE. Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Invest Ophthalmol Vis Sci 2005; 46: 1092-8.
112. Peng PH, Huang HS, Lee YJ, Chen YS, Ma MC. Novel role for the delta-opioid receptor in hypoxic preconditioning in rat retinas. J Neurochem 2009; 108: 741-54.
113. Husted TL, Govindaswami M, Oeltgen PR., Rudich SM, Lentsch AB. A delta2-opioid agonist inhibits p38 MAPK and suppresses activation of murine macrophages. J Surg Res 2005; 128: 45-9.
114. Welters ID, Menzebach A, Goumon Y, et al. Morphine inhibits NF-kappaB nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism. Anesthesiology 2000; 92: 1677-84.
115. Muller DL, Unterwald EM. In vivo regulation of extracellular signal-regulated protein kinase (ERK) and protein kinase B (Akt) phosphorylation by acute and chronic morphine. J Pharmacol Exp Ther 2004; 310: 774-82.
116. Kikuchi M, Tenneti L, Lipton SA. Role of p38 mitogen-activated protein kinase in axotomy-induced apoptosis of rat retinal ganglion cells. J Neurosci 2000; 20: 5037-44.
117. Levkovitch-Verbin H, Harizman N, Dardik R, Nisgav Y, Vander S, Melamed S. Regulation of cell death and survival pathways in experimental glaucoma. Exp Eye Res 2007; 85: 250-8.
118. Clemens JA, Stephenson DT, Smalstig EB, Dixon EP, Little SP. Global ischemia activates nuclear factor-kappa B in forebrain neurons of rats. Stroke 1997; 28: 1073-80; discussion 1080-1.
119. Schmidt KN, Amstad P, Cerutti P, Baeuerle PA. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. Chem Biol 1995; 2: 13-22.
120. Kaltschmidt C, Kaltschmidt B, Baeuerle PA. Stimulation of ionotropic glutamate receptors activates transcription factor NFkappa B in primary neurons. Proc Natl Acad Sci USA 1995; 92: 9618-22.
121. Kitaoka Y, Kwong JM, Ross-Cisneros FN, et al. TNF-alphainduced optic nerve degeneration and nuclear factor-kappaB p65. Invest Ophthalmol Vis Sci 2006; 47: 1448-57.
122. Schabbauer G, Tencati M, Pedersen B, Pawlinski R, Mackman N. PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Arterioscler Thromb Vasc Biol 2004; 24: 1963-9.
123. Fukunaga K, Kawano T. Akt is a molecular target for signal transduction therapy in brain ischemic insult. J Pharmacol Sci 2003; 92: 317-27.
124. Dreixler JC, Hemmert JW, Shenoy SK, et al. The role of Akt/protein kinase B subtypes in retinal ischemic preconditioning. Exp Eye Res 2009; 88: 512-21.
125. Alexaki VI, Charalampopoulos I, Kampa M, et al. Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation. FASEB J 2004; 18: 1594-6.
126. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002; 277: 32124-32.
127. Yu Y, Nagai S, Wu H, Neish AS, Koyasu S, Gewirtz AT. TLR5-mediated phosphoinositide 3-kinase activation negatively regulates flagellin-induced proinflammatory gene expression. J Immunol 2006; 176: 6194-201.
128. Zhao L, Lee JY, Hwang DH. The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NFkappaB pathway. Biochem Pharmacol 2008; 75: 1515-25.
129. Levresse V, Butterfield L, Zentrich E, Heasley LE. Akt negatively regulates the cJun N-terminal kinase pathway in PC12 cells. J Neurosci Res 2000; 62: 799-808.
130. Yang Y, Xia X, Zhang Y, et al. delta-Opioid receptor activation attenuates oxidative injury in the ischemic rat brain. BMC Biol 2009; 7: 55.
131. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci 1993; 13: 2651-61.
132. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-37.
133. Muijsers RB, Folkerts G, Henricks PA, Sadeghi-Hashjin G, Nijkamp FP. Peroxynitrite: a two-faced metabolite of nitric oxide. Life Sci 1997; 60: 1833-45.
134. Ryter SW, Kim HP, Hoetzel A, et al. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 2007; 9: 49-89.
135. Keating DJ, Rychkov GY, Adams MB, Holgert H, McMillen IC, Roberts ML. Opioid receptor stimulation suppresses the adrenal medulla hypoxic response in sheep by actions on Ca(2+) and K(+) channels. J Physiol 2004; 555: 489-502.
136. Bie B, Zhu W, Pan ZZ. Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses. J Pharmacol Exp Ther 2009; 329: 290-6.
137. Glaum SR, Miller RJ, Hammond DL. Inhibitory actions of delta 1-, delta 2-, and mu-opioid receptor agonists on excitatory transmission in lamina II neurons of adult rat spinal cord. J Neurosci 1994; 14: 4965-71.
138. Chao D, Balboni G, Lazarus LH, Salvadori S, Xia Y. Na+ mechanism of delta-opioid receptor induced protection from anoxic K+ leakage in the cortex. Cell Mol Life Sci 2009; 66: 1105-15.
139. Pamenter ME, Buck LT. delta-Opioid receptor antagonism induces NMDA receptor-dependent excitotoxicity in anoxic turtle cortex, J Exp Biol 2008; 211: 3512-7.
140. Zhu M, Li MW, Tian XS, Ou XM, Zhu CQ, Guo JC. Neuroprotective role of delta-opioid receptors against mitochondrial respiratory chain injury. Brain Res 2009; 1252: 183-91.
141. Tsao LI, Ladenheim B, Andrews AM, Chiueh CC, Cadet JL, Su TP. Delta opioid peptide [D-Ala2, D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: involvement of opioid receptors and reactive oxygen species. J Pharmacol Exp Ther 1998; 287: 322-31.